COZADD BRUCE C 4

What Happened Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), sold 6,000 shares in an open-market transaction on May 1, 2026 at $203.33 per share, generating proceeds of $1,219,980. This was a sale (not a purchase) and represents an insider disposition rather than a bullish purchase signal.

Key Details

• Transaction type: Sale (S) — open market/private sale reported on Form 4.
• Date and price: May 1, 2026 — 6,000 shares at $203.33 per share.
• Proceeds: $1,219,980 (gross).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing date: May 5, 2026 (filing appears timely for a Form 4 reporting a May 1 trade).
• Footnote: Transaction was made under a Rule 10b5-1 trading plan adopted Nov 26, 2025; the trade occurred automatically and was not a discretionary decision by the reporting person.

Context A 10b5-1 plan lets insiders pre-schedule trades, so sales under such plans are often automatic and should not be taken alone as a signal of the insider’s current view of the company. Sales provide liquidity or portfolio diversification and are common; they do not necessarily indicate negative company-specific information.